Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.49 |
| ▸ | DGKA | P23743 | 1/20 | 0.49 |
| ▸ | KDM5A | P29375 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PAM | P19021 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18707721 | 0.92 | KDM5A (0.55) | DNM1DGKAKDM5ALMNAALDH1A1 | |
| SCHEMBL10743398 | 0.90 | DGKA (0.50) | DNM1DGKALMNAALDH1A1PAM | |
| SCHEMBL13746621 | 0.89 | DNM1 (0.50) | DNM1DGKAKDM5ALMNAALDH1A1 | |
| SCHEMBL26007 | 0.88 | CYP1A2 (0.54) | DNM1DGKAKDM5ALMNAALDH1A1 | |
| SCHEMBL5496454 | 0.88 | CYP1A2 (0.39) | DNM1DGKAKDM5ALMNAALDH1A1 | |
| SCHEMBL12082605 | 0.88 | DNM1 (0.43) | DNM1DGKAKDM5ALMNAPAM | |
| SCHEMBL12082682 | 0.88 | DNM1 (0.43) | DNM1DGKAKDM5ALMNAPAM | |
| SCHEMBL12082588 | 0.86 | DNM1 (0.41) | DNM1DGKAKDM5ALMNAALDH1A1 | |
| SCHEMBL20880020 | 0.84 | ALDH1A1 (0.44) | KDM5AALDH1A1KDM4CCYP1A2 | |
| SCHEMBL10738938 | 0.83 | ALDH1A1 (0.48) | DNM1DGKALMNAALDH1A1PAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12031133-B2 | GNAQ targeted dsRNA compositions and methods for inhibiting expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230340473-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | ALNYLAM PHARMACEUTICALS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20180216115-A1 | Compositions and Methods for Inhibiting Expression of the PCSK9 Gene | BANK OF AMERICA, N.A. | 2018-08-02 | — | — | US | disclosed |
| US-20180171332-A1 | siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis | ALNYLAM PHARMACEUTICALS, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180127749-A1 | Compositions and Methods for Inhibiting Expression of Factor V | BANK OF AMERICA, N.A. | 2018-05-10 | — | — | US | disclosed |
| US-9963700-B2 | GNAQ targeted dsRNA compositions and methods for inhibiting expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9957507-B2 | Compositions and methods for inhibiting expression of mutant EGFR gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9868950-B2 | Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9822365-B2 | Compositions and methods for inhibiting expression of the PCSK9 gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170321213-A1 | Compositions and Methods for Inhibiting Expression of Transthyretin | BANK OF AMERICA, N.A. | 2017-11-09 | — | — | US | disclosed |
| US-20110105590-A1 | Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes | VORNLOCHER HANS-PETER | 2011-05-05 | — | — | US | disclosed |
| US-7928217-B2 | Drug delivery of nucleotide into tumor; antitumor biodrugs; stability in cells; prevent gene expression of target genes | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20110071209-A1 | RNAi Modulation of the RHO-A Gene and Uses Thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110060031-A1 | Compositions And Methods For Inhibiting Expression Of A Gene From The Ebola Virus | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110034537-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD45 GENE | BANK OF AMERICA, N.A. | 2011-02-10 | — | — | US | disclosed |
| US-20110015252-A1 | LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE | BANK OF AMERICA, N.A. | 2011-01-20 | — | — | US | disclosed |
| US-20110015250-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 GENE | ALNYLAM PHARMACEUTICALS, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20110003882-A1 | RNAi Modulation of AHA and Therapeutic Uses Thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20100003317-A1 | COMPOSITIONS AND METHODS FOR MEDIATING RNAI IN VIVO | BANK OF AMERICA, N.A. | 2010-01-07 | — | — | US | disclosed |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180171332-A1 | siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis | TTR, CRYAA, SARNP | DNM1 2320/4885DGKA 1815/4885KDM5A 4682/4885 |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | DNM1 1226/4885DGKA 1806/4885KDM5A 3021/4885 |
| US-20110034537-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD45 GENE | PTPRC, PTPRCAP, DDX21 | DNM1 743/4885DGKA 315/4885KDM5A 792/4885 |
| US-20110060031-A1 | Compositions And Methods For Inhibiting Expression Of A Gene From The Ebola Virus | EIF2AK2, DDX39B, STING1 | DNM1 1811/4885DGKA 624/4885KDM5A 3023/4885 |
| US-12031133-B2 | GNAQ targeted dsRNA compositions and methods for inhibiting expression | GNAQ, GNAI1, GNAI2 | DNM1 211/4885DGKA 15/4885KDM5A 3930/4885 |
| US-20100003317-A1 | COMPOSITIONS AND METHODS FOR MEDIATING RNAI IN VIVO | FABP3, MYLK2, TNNC1 | DNM1 172/4885DGKA 117/4885KDM5A 3349/4885 |
| US-20180216115-A1 | Compositions and Methods for Inhibiting Expression of the PCSK9 Gene | PCSK9, PCSK7, RNASE1 | DNM1 1827/4885DGKA 189/4885KDM5A 2712/4885 |
| US-20110071209-A1 | RNAi Modulation of the RHO-A Gene and Uses Thereof | RHOA, ARHGDIA, RHOC | DNM1 119/4885DGKA 294/4885KDM5A 1926/4885 |
| US-20110015250-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 GENE | GEMIN5, KIF5A, KIF5C | DNM1 1998/4885DGKA 696/4885KDM5A 296/4885 |
| US-20110015252-A1 | LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE | PCSK9, PCSK7, PCSK6 | DNM1 1539/4885DGKA 29/4885KDM5A 3286/4885 |
| US-20170321213-A1 | Compositions and Methods for Inhibiting Expression of Transthyretin | TTR, RNGTT, RNASE1 | DNM1 2568/4885DGKA 1268/4885KDM5A 3286/4885 |
| US-20110105590-A1 | Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes | BCL2, BAK1, BBC3 | DNM1 585/4885DGKA 857/4885KDM5A 4249/4885 |
| US-20230340473-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | TTR, CRYAA, SARNP | DNM1 2320/4885DGKA 1815/4885KDM5A 4682/4885 |
| US-20180127749-A1 | Compositions and Methods for Inhibiting Expression of Factor V | F5, F13B, F13A1 | DNM1 3806/4885DGKA 2253/4885KDM5A 3378/4885 |
| US-20110003882-A1 | RNAi Modulation of AHA and Therapeutic Uses Thereof | AHSA1, MTREX, RNASEH1 | DNM1 1128/4885DGKA 784/4885KDM5A 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.